Table 3.
Baseline characteristics of darunavir and atazanavir users and the general HIV-1–infected population in the USA
| Parameter | MDCD | CCAE | Optum | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HIV-1–infected (n = 80,522) | Darunavir users (n = 4637) | Atazanavir users (n = 4664) | HIV-1–infected (n = 220,589) | Darunavir users (n = 8360) | Atazanavir users (n = 8977) | HIV-1–infected (n = 149,145) | Darunavir users (n = 4771) | Atazanavir users (n = 6413) | |
| Gender, n (%) | |||||||||
| Female | 36,024 (45) | 2057 (44) | 2376 (51) | 53,985 (24) | 1536 (18) | 1955 (22) | 40,717 (27) | 795 (17) | 1187 (19) |
| Male | 44,498 (55) | 2580 (56) | 2288 (49) | 166,604 (76) | 6824 (82) | 7022 (78) | 108,428 (73) | 3976 (83) | 5226 (81) |
| Age, years | |||||||||
| Mean (SD) | 41.0 (14.3) | 42.6 (11.9) | 40.8 (12.0) | 41.3 (11.6) | 44.7 (10.4) | 42.9 (10.1) | 42.3 (13.2) | 47.2 (11.1) | 43.6 (10.2) |
| < 50, n (%) | 57,548 (71) | 3211 (69) | 3491 (75) | 163,479 (74) | 5424 (65) | 6608 (74) | 107,958 (72) | 2757 (58) | 4757 (74) |
| ≥ 50, n (%) | 22,973 (29) | 1426 (31) | 1173 (25) | 57,110 (26) | 2936 (35) | 2369 (26) | 41,187 (28) | 2014 (42) | 1656 (26) |
| Comorbidities, % | |||||||||
| CV disorder | 30 | 64 | 52 | 23 | 50 | 38 | 29 | 61 | 44 |
| Metabolic disorder | 26 | 57 | 44 | 25 | 51 | 38 | 33 | 65 | 49 |
| Hypertension | 21 | 45 | 35 | 15 | 31 | 22 | 19 | 41 | 26 |
| Hyperlipidemia | 10 | 27 | 18 | 17 | 37 | 26 | 25 | 50 | 37 |
| Diabetes | 9 | 17 | 12 | 7 | 10 | 8 | 10 | 15 | 9 |
CCAE Truven Health MarketScan® Commercial Claims and Encounters database, CV cardiovascular, HIV-1 human immunodeficiency virus-1, MDCD Truven Health MarketScan® Medicaid database, Optum Optum Clinformatics™ Extended DataMart Socio-Economic Status database, SD standard deviation